加载中
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
常规交易时段
US$17.81
−US$0.45 · -2.46%
盘中时间采用ET。市场数据可能有所延迟。
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
日内区间
当前US$17.81
52周区间
当前US$17.81
盘中时间采用ET。市场数据可能有所延迟。
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
日内区间
当前US$17.81
52周区间
当前US$17.81
| 项目（USD） | 2025财年 |
|---|---|
| 营收 | 297.6万 USD |
| 毛利 | 297.6万 USD |
| 研究与开发 | 1.27亿 USD |
| 销售、一般及管理费用 | 3751.6万 USD |
| 营业费用 | 1.64亿 USD |
| 利息收入 | 634.8万 USD |
| 利息支出 | 1.7万 USD |
| 折旧和摊销 | 491.1万 USD |
| 营业利润 | −1.61亿 USD |
| 净利润 | −1.49亿 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1302.25万0.00%2.3万亿 USD0.03%US$380.94-0.17%
iShares Russell 2000 ETFIWM767.98万0.01%787.4亿 USD0.19%US$276.19-0.62%
Vanguard Extended Market ETFVXF442.74万0.00%954亿 USD0.05%US$232.09-0.61%
iShares Russell 2000 Growth ETFIWO165.2万0.01%139.17亿 USD0.24%US$350.94-0.78%
Schwab U.S. Small-Cap ETFSCHA152.39万0.01%217.13亿 USD0.03%US$32.475-0.57%
iShares Russell 2000 Value ETFIWN106.89万0.01%137.49亿 USD0.24%US$210.25-0.40%
iShares Micro-Cap ETFIWC95.73万0.07%13.17亿 USD0.60%US$179.98-0.93%
Vanguard Russell 2000 ETFVTWO29.14万0.00%180亿 USD0.06%US$111.55-0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Value ETFIWNiShares Micro-Cap ETFIWCVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
